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ABSTRACT
The burden of pneumococcal disease in adults is substantial from a social and economic point of view.
This study assessed the cost-effectiveness of the 13-valent pneumococcal conjugate vaccine (PCV13) for
the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults versus “no
vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
A Markov model was used to simulate three strategies: no vaccination, complete vaccination with
PPSV23 and complete vaccination with PCV13. The comparison between strategies allowed the estima-
tion of clinical and economic outcomes including incremental cost-effectiveness ratios (ICER) and
incremental cost-utility ratios (ICUR). The model took into account the distributions of age, risk profile,
vaccination status, type of immunization and time since vaccination in the population. A societal
perspective was adopted and a lifetime horizon was considered. Different sources of data and assump-
tions were used to calibrate PPSV23 and PCV13 effectiveness. Inpatient costs were based on the 2013
diagnosis-related group (DRG) database for National Health Service (NHS) hospitals and expert opinion;
NHS official tariffs were the main source for unitary costs. PCV13 shows ICURs of €17,746/QALY and
€13,146/QALY versus “no vaccination” and vaccination with PPSV23, respectively. Results proved to be
robust in univariate sensitivity analyses, where all ratios were below a €20,000 threshold, with the
exception of the scenario with PCV13 effectiveness halved. In a probabilistic sensitivity analysis, 94% of
simulations showed cost-effectiveness ratios lower than €20,000/QALY, in both strategies. It was found
that PCV13 is a cost-effective strategy to prevent pneumococcal disease in adults in Portugal.
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Pneumococcal disease (PD) is caused by Streptococcus pneumo-
niae (S. pneumoniae or SP), a bacterium responsible for a large
spectrum of infections that can be classified as invasive (e.g.,
septicemia and meningitis) or non-invasive (e.g., pneumonia
without bacteremia or pleural effusion).1 The burden of PD in
adults is substantial, both from a societal and an economic point
of view,2 since PD is responsible for about 1.6 million annual
deaths worldwide.3
According to the Portuguese National Statistics Institute
(PNSI), no major variation in the pneumonia mortality rate
has been documented in recent years. Pneumonia was respon-
sible for almost 6,000 deaths in 2013 in Portugal.4 The pneu-
monia-related standardized mortality rate in Portugal is 25.1
deaths per 100,000 inhabitants, according to the last available
report from the Directorate-General of Health.5 Community-
acquired pneumonia (CAP) is associated with significant
health care resource consumption both in outpatient and
especially in hospital settings.6–8 In Portugal, 93% of CAP-
related hospitalizations occur in adults.9 In addition to an
increased risk of morbidity and mortality, pneumonia signifi-
cantly decreases health-related quality of life. After
a pneumonia episode, resuming daily activities and fully reco-
vering global function may take four weeks or more.10–12
Despite the use of antibiotics, PD remains an important disease
with a significant impact on adult morbidity and mortality, sug-
gesting that vaccination is likely to be the only intervention with
a significant impact on the incidence of pneumococcal pneumonia
and invasive pneumococcal disease (IPD), as highlighted by the
World Health Organization (WHO).13 The 13-valent pneumo-
coccal conjugate vaccine (PCV13) is indicated for the prevention
of invasive disease, pneumonia and acute otitis media caused by
S. pneumoniae. Except for otitis, the approved population includes
all age groups.14 In July 2015, PCV13 was included in the
Portuguese National Immunization Program for infants born
after January 1, 2015.15 Two 2015 guidelines from the national
Directorate-General of Health further define the risk groups for
IPD in individuals under 18 years old16 and over 18 years old17 for
which PCV13 is recommended (either with co-payment or free of
charge). In immunocompetent adults, PCV13 vaccination is
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recommended for individuals with cerebrospinal fluid fistulas or
cochlear implants, patients with some chronic diseases (e.g.,
diabetes, heart, respiratory, liver and renal diseases), pre-
transplantation patients, and bonemarrow donors.17 In immuno-
compromised adults, PCV13 is recommended for individuals with
asplenia or splenic dysfunction, active neoplastic disease, trans-
plant recipients, primary immunodeficiency, human immunode-
ficiency virus (HIV) infection, nephrotic syndrome, iatrogenic
immunosuppression, or Down syndrome.17
In this context, it is relevant to estimate the cost-
effectiveness of PCV13 for the prevention of IPD and pneu-
monia in adults, compared to “no vaccination” and to the
other available vaccine (23-valent pneumococcal polysacchar-
ide vaccine: PPSV23), in the Portuguese setting.
Results
In the base-case scenario considering the overall Portuguese
adult population (18 years and older) over a lifetime horizon,
PCV13 averted 5,712 and 5,597 deaths for PD when compared
to “no vaccination” and PPSV23, respectively. The PCV13-
attributable reduction of in-hospital PD episodes was 25,104
and 4,813 versus “no vaccination” and PPSV23, respectively.
PCV13 was associated with an increase in quality-adjusted
life-years (QALYs) and life-years (LY) at an expense of higher
costs versus “no vaccination” and PPSV23. Overall, the life-
time per-patient additional costs of the PCV13 vaccination
strategy were €47 and €33 versus “no vaccination” and
PPSV23, respectively. Cost-effectiveness ratios were higher
versus “no vaccination” than versus PPSV23, both considering
LY gained (LYG) (incremental cost-effectiveness ratio [ICER]:
€11,082/LYG versus €8,151/LYG) and QALYs (incremental
cost-utility ratio [ICUR]: €17,746/QALY versus €13,146/
QALY) (Table 1).
Results for univariate sensitivity analyses showed some
variation of cost-effectiveness ratios around the base-case
results, although all ratios were below the €20,000 threshold
with the exception of the scenario where PCV13 effectiveness
was reduced by 50% (ICER €23,570/LYG and €18,650/LYG;
ICUR: €37,515/QALY and €30,096/QALY; both versus “no
vaccination” and PPSV23, respectively) (Table 2).
Probabilistic sensitivity analysis (PSA) results were consis-
tent with the deterministic results for the base-case scenario,
since 94% of the simulations showed cost-effectiveness ratios
lower than €20,000/QALY, in both comparisons.
PCV13 vaccination strategy outperforms “no vaccination”
with at least a 50% probability if willingness-to pay (WTP) for
an incremental QALY is above €15,000/QALY, with a 75%
probability if WTP is above €17,000/QALY and in all simula-
tions if the WTP is above €25,900/QALY. The PCV13 vaccina-
tion strategy outperforms the PPSV23 vaccination strategy with
at least a 50% probability if the WTP is above €10,900/QALY,
with a 75% probability if the WTP is above €12,600/QALY and
in all simulations if the WTP is above €24,100/QALY.
Discussion
The results of this cost-effectiveness study comparing the
PCV13 vaccination strategy versus “no vaccination” and
PPSV23 show that PCV13 is a cost-effective option for the
overall Portuguese adult population, with ICERs of €17,746/
QALY and €13,146/QALY, respectively. These results proved
robust to a variety of changes in the model parameters and
assumptions. In almost all univariate analyses, the ICER was
below €20,000/QALY. The robustness of these results is rein-
forced by PSA in which 94% of the simulations showed cost-
effectiveness ratios lower than €20,000/QALY both in com-
parison to “no vaccination” and to vaccination with PPSV23.
This study has several limitations. First, the PCV13 effective-
ness source used in the analysis (Community-Acquired
Pneumonia Immunization Trial in Adults [CAPiTA])20 included
Table 1. Results of base-case scenario.
PCV13 No vaccine PPSV23
Overall number of PD episodes over the lifetime horizon in the
population
Bacteremia or sepsis infections 29,728 32,200 30,389
Meningitis infections 6,471 7,131 6,642
Inpatient pneumonia 2,372,771 2,396,994 2,397,043
Outpatient pneumonia 3,203,157 3,252,062 3,252,130
Deaths for PD 641,565 647,277 647,162
Outcomes and costs per capita
LY 15.206 15.202 15.202
QALY 12.048 12.045 12.045
Costs (€) 407.03 360.38 373.92
Cost-effectiveness and costs-utility ratios
ICER
PCV13 vs. no vaccine 11,082 €/LYG
PCV13 vs. PPSV23 8,151 €/LYG
ICUR
PCV13 vs. no vaccine 17,746 €/QALY
PCV13 vs. PPSV23 13,146 €/QALY
LY = Life-years; LYG = Life-year gained; QALY = Quality-adjusted life-years;
ICER = Incremental cost-effectiveness ratio; ICUR = incremental cost-utility
ratio.













Base-case 8,151 13,146 11,082 17,746





8,151 13,146 11,570 18,526
Discount rate 0% 4,214 6,803 5,764 9,234
3% 6,429 10,374 8,766 14,041
Herd effect No herd effect 8,045 12,974 10,802 17,270





2,590 4,408 3,931 6,675
Inpatient CAP
incidence
−20% 10,476 16,904 13,937 22,292
+20% 6,591 10,620 9,142 14,641
Outpatient CAP
incidence
−20% 8,409 13,648 11,331 18,254
+20% 8,086 13,022 11,020 17,620
Effectiveness of
PCV13
−50% 18,650 30,096 23,570 37,515
+50% 2,825 4,556 4,416 7,095
CAP = Community-acquired pneumonia; LYG = Life-Year-Gained; QALY = Quality-
adjusted life years; ICER = Incremental cost-effectiveness ratio; ICUR = incremental
cost-utility ratio. aUnit cost for non-urgent transportation to Primary Care was
recently estimated for Portugal at 4.10€ (two ways).18 We assumed 50% of users
have a contact with the system only because of vaccination. bUptake rates of
vaccination similar to the immunization rate reported in Portugal in 2015–2016
for Influenza vaccination.19
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only immunocompetent adults aged 65 years or older. In our
study, the analysis considered the overall adult population (aged
18 years and older) for which PCV13 is reimbursed in Portugal.
Therefore, adjusted PCV13 effectiveness was estimated for other
age groups considering the rate of change of PPSV23 effectiveness
with age (see SupplementaryMaterial, Table S2 for further detail).
Although this assumption introduces uncertainty, it seems rea-
sonable because PCV13 vaccination has proven to be effective in
both children21-24 and the elderly, both in clinical trial 20 and real
world settings.25 PCV13 is likely to have similar efficacy in
younger adults as immune responses in this population are com-
parable or better than in older adults.26 In fact, in the case of
PPSV23, effectiveness was also documented for the younger adult
population for IPD27 being even higher in this population (18 to
55 years). Furthermore, our results proved quite robust when
PCV13 effectiveness was hypothetically halved in a univariate
sensitivity analysis (Table 2).
Second, to the best of our knowledge, no head-to-head trial
exists comparing PCV13 and PPSV23 efficacy in adult popu-
lations. Therefore, different sources and assumptions were
used to calibrate PCV13 and PPSV23 effectiveness.
Third, the epidemiological calibration of the model was
based on the diagnosis-related group (DRG) administrative
database. It has been reported that the ICD coding scheme in
DRGs may be inaccurate in the classification of patients with
IPD.28 Furthermore, ICD-9 codes have been associated with
low to modest sensitivity for detecting CAP in hospital
administrative databases. In particular, at least one quarter
of pneumonia cases are undetected. Therefore, the true inci-
dence of inpatient CAP has probably been underestimated in
our study, although the incidence rates of hospitalised CAP
reported in this study are similar to other European estima-
tions from studies conducted in Denmark, Finland, France,
Hungary, Poland and Norway.29 Our results also proved
robust when the incidence rate of inpatient pneumonia varied
by ± 20% (Table 2).
Fourth, the analysis assumed an immunization rate of
100% among adults. Although this rate of immunization is
impossible to achieve, this assumption has been used in pre-
vious studies28,30,31 and probably represents a conservative
approach. The model only took into consideration the herd
effects from the paediatric vaccination program and not the
potential small benefits associated with herd protection
externalities generated by adults’ vaccination,32 although the
pneumococcal carriage rate in adults is very low (<5% in
CAPiTA study).20 In this study, the inclusion of herd effect
generated by children’s vaccination leads to a reduction in the
incidence of IPD among the adult population, therefore redu-
cing the maximum public health potential benefits of vacci-
nating adults. In fact, the cost-effectiveness ratio (Table 2) is
lower when herd effects from childhood vaccination are
excluded from the analysis. The model assumes a linear link
between impact and costs of the vaccination program.
Therefore, providing that immunization rate is similar across
all age groups, coverage does not affect the cost-effectiveness
results. In a sensitivity analysis, we explored the effect of
different uptake rates of vaccination among adults age groups
by considering the immunization rate reported in Portugal in
2015–2016 for Influenza vaccination (50.1% in subjects
≥65 years and 5.0% in younger adults).19 In comparison to
the base-case scenario, the PCV13 ICER in this sensitivity
analysis is lower versus both PPSV23 and no vaccination,
due to the higher uptake rate among people which benefit
the most from vaccination.
Most previously published adult PCV13 cost-effectiveness
studies assumed that the effectiveness of adult vaccination is
similar to the paediatric effectiveness.8,30,34–37 The current
study employs effectiveness estimates specific to the adult
population, based on the published CAPiTA study,20 which
may increase the accuracy of the results hereby presented.
Recent European cost-effectiveness studies of PCV13 vaccina-
tion in the adult population that used effectiveness data from
the CAPiTA study present considerable variability in
results.39–47 The heterogeneity of the results in published
literature might be explained by differences in the compara-
tors (PPSV23 or no vaccination), target age for vaccination,
assumptions regarding resource use and costs, approaches
followed to include the indirect effect of childhood vaccina-
tion in the models, dynamics of vaccination serotype coverage
over time, calibration of the PPSV23 effectiveness and the
incidence rate of IPD in adult population, in particular of
hospitalized pneumonia.
The impact that some parametric options (calibration and
modelling) have on the cost-effectiveness results of PCV13 in
particular, and of immunization programs in general, high-
lights the need to be cautious in interpreting and extrapolat-
ing results of one particular study for other settings.
Materials and methods
Model structure
A cohort model with a Markov-type process (cycle length of
one year) was used to estimate the clinical and economic out-
comes of PCV13 vaccination, which include incremental cost-
effectiveness and cost-utility ratios. The model starts from the
overall Portuguese population aged 18 years or older and
follows this cohort throughout the modelling horizon under
three different strategies: no immunization, 100% immuniza-
tion with PPSV23 and 100% immunization with PCV13
(“intervention strategy”). Results compare the intervention
strategy with the other two alternative strategies. A lifetime
modelling horizon was considered in base-case analyses for
all cohorts. Benefits and costs were discounted at 5% as recom-
mended by the National Authority of Medicines and Health
Products (INFARMED) guidelines.48 The model estimates the
disease risk (incidence and fatality) based on population char-
acteristics (distribution per age and risk profile). This model
has been previously validated for other countries and used as
a basis for publications by other authors.42,45 The economic
model structure is presented in Figure 1.
Expected outcomes were evaluated for each person in the
model population on an annual basis, taking into consideration
age, risk profile, vaccination status, type of immunization
(PCV13 or PPSV23) and time since vaccination. Clinical results
include the estimation in each scenario of IPD incidence (inpa-
tient), number of hospitalizations and outpatient visits asso-
ciated with pneumonia, mortality due to CAP or IPD, life-
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years and quality-adjusted life-years. Economic results presented
include direct medical and indirect costs due to loss of produc-
tivity, and incremental cost-effectiveness and cost-utility ratios.
Demographic and epidemiological parameters
Estimates of the overall continental Portuguese population
aged 18 years and older were obtained from National
Statistics Office (INE) for 2013.49 Population was grouped
according to the level of risk for PD and/or related complica-
tions: 1) low-risk individuals are immunocompetent without
any chronic medical conditions; 2) moderate-risk includes
immunocompetent individuals with one or more chronic
medical conditions, such as cardiovascular, liver, or pulmon-
ary disease, or diabetes; 3) high-risk includes immunocom-
promised individuals as a result of splenic dysfunction,
neoplasms (including Hodgkin’s disease, lymphoma), HIV,
organ transplant, or chronic renal failure.50
The proportion of individuals in each age group with low,
moderate, or high risk was estimated using National Health
Survey 2005/2006 microdata.51 These were the most recent
available data at the time of the analysis. The high-risk group
prevalence was adjusted in order to include HIV prevalence
estimates since these were not available in the National Health
Survey. Retrieving data from official annual reports,52,53 HIV
prevalence by sex and age was estimated considering year of
diagnosis, mortality by year of diagnosis and patient age.
The incidence of IPD was estimated in two steps. First, the
incidence of pneumococcal bacteremia, sepsis and meningitis
were taken into account. Second, the serotype coverage of
PCV13 and PPSV23 were factored in. In the case of pneumo-
nia, the model was calibrated with the incidence for both
inpatient and outpatient all-cause nonbacteremic pneumonia.
This calibration is due to the fact that the model considers
vaccine effectiveness rates against all-cause nonbacteremic
pneumonia.
Pneumococcal bacteremia incidence was estimated from
unpublished data. Since 1999, the Portuguese Group for the
Study of Streptococcal Infections has monitored pneumococci
causing invasive infections in Portugal. This is a laboratory-
based surveillance system, in which 30 microbiology labora-
tories throughout Portugal are asked to identify all isolates
responsible for IPD and to send them to a central laboratory
for characterization.54 For the purpose of our study, we had
access to detailed data from 1,265 isolates responsible for
adult IPD between 2009 and 2011, which allowed us to esti-
mate Pneumococcal bacteremia incidence rates by age-group
in 2011.
Pneumococcal meningitis, pneumococcal sepsis and overall
inpatient pneumonia incidence rates were estimated using
2013 microdata from the DRG database that includes the
discharges from Portuguese public hospitals.55 Since
a significant number of meningitis and sepsis episodes had
no pathogen identified, the proportion of pneumococcal dis-
ease in the group of invasive infections with an unidentified
pathogen was assumed to be the same as in episodes with an
identified pathogen. Supplementary Table S1 presents the
ICD-9 codes used to select the relevant episodes. The percen-
tage of bacteremia and meningitis cases due to SP serotypes
covered by the vaccine was estimated from Horácio et al.
(2013)56 for all IPD. It was assumed that the serotypes respon-
sible for the meningitis and bacteremia were the same as the
serotypes responsible for all IPD.
Due to lack of data, we assumed that outpatient pneumonia
incidence rates for Portugal were proportional to inpatient rates
multiplied by the ratio between the outpatient and inpatient
pneumonia incidence rates found in the US population.56
Portuguese general population mortality rates for all causes
were calibrated using published mortality tables for 2011/
201357 and adjusted for mortality due to meningitis, bacteremia
and pneumonia, in order to avoid double counting.
Pneumonia-specific mortality rates for 2013 were published
by INE.58 PD mortality rates were estimated from the 2013
DRG database55 considering the episodes with a primary diag-
nosis of pneumococcal meningitis (ICD-9-CM 320.1), pneu-
mococcal septicemia (ICD-9-CM 038.2), bacteremia1 (ICD-
9-CM 790.7) or pneumococcal pneumonia (ICD-9-CM 481).
Utility values by age group and sex were taken from Sisk
et al. (2003)59 and disutilities associated with each disease
were the same as in Melegaro and Edmunds (2004).60
Table 3 describes the main demographic and epidemiolo-
gical parameters used in the base-case scenario, as well as
health-state utilities and yearly disutilities.
Effectiveness of PCV13 and PPSV23
Different sources of data and assumptions were used to calibrate
effectiveness results for PPSV23 and PCV13. For both, effective-
ness data were estimated according to age group, risk group and
time since vaccination for each outcome (IPD and pneumonia).
For PPSV23, the model included data reported by Smith et al.
(2008),33 which estimated the cost-effectiveness of PPSV23 ver-
sus “no vaccination” among adults aged 50 years and over. In the
Smith et al. study,33 effectiveness of PPSV23 in preventing IPD
was based on a Delphi panel of experts. The panel primarily









Figure 1. Economic model.
IPD: invasive pneumococcal disease. CAP: Community Acquired PneumoniaAll
transition probabilities vary with age, risk profile (low, moderate or high) and
time since vaccination.
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based case-control study evaluating PPSV23 effectiveness
(Supplementary Material, Table S2).
Effectiveness of PPSV23 against all-cause nonbacteremic
pneumonia was considered to be null, as assumed in other
studies.31,33,61–67 The rate of decline in PPSV23 effectiveness
against vaccine-type IPD over time was based on Smith et al.
(2008),33 and was applied beginning one year following
vaccination.
For PCV13, effectiveness was based on the results of the per-
protocol population of the CAPiTA study20 (Supplementary
Material, Table S2). CAPiTA20 was a randomized, double-
blind, placebo-controlled trial involving 84,496 adults aged
65 years or older, evaluating the efficacy of PCV13 in preventing
first episodes of vaccine-type strains of pneumococcal CAP,
nonbacteremic and non-invasive pneumococcal CAP, and IPD.
Per-protocol population included all participants who met the
criteria for the modified intention-to-treat population (episode
of CAP or IPD with the onset of symptoms at least 14 days after
vaccination), were eligible for the study (absence of immuno-
compromising conditions), received a vaccination and had no
other major protocol violations.
Effectiveness of PCV13 against all-cause nonbacteremic
pneumonia was estimated as the product of PCV13 efficacy
in preventing vaccine-type nonbacteremic and non-invasive
CAP20 and the proportion of all-cause nonbacteremic pneu-
monia due to PCV13 serotypes (19.4%), as reported for the
Spanish population67 (Supplementary Material, S3). It was
assumed that PCV13 effectiveness in preventing IPD and
pneumonia did not wane over the initial 5 years of the
modelling horizon, based on the observation that PCV13
effectiveness appeared to be stable during the CAPiTA follow-
up period (mean, 3.97 years).20 Afterwards, it was assumed
that the rate of PCV13 effectiveness decline was 50% of the
PPSV23 effectiveness decline (Supplementary Material, Table
S2 and Table S3).
Effectiveness of both vaccines was assumed to be the same
irrespective of previous vaccination experience and no revac-
cination was assumed. Effectiveness of each vaccine (i.e.,
PPSV23 and PCV13) across vaccine-specific serotypes was
assumed to be the same.
The model includes the herd effect due to widespread use in
of PCV13 in young children. The herd effect on IPD is based on
estimates by Miller et al. (2013) for England and Wales.68 The
elasticity of adult IPD incidence reduction took into account the
difference in vaccine coverage between Portugal (61%)69 and
England/Wales (96%).70 The indirect effect of PCV13 on all-
cause nonbacteremic pneumonia is less well studied. In line with
other authors,71 it was assumed that for Portugal this effect
would be proportional to the IPD herd effect, representing on
average a 1% reduction in pneumonia incidence.
Resource use and costs
Inpatient costs by age group were estimated using 2013 DRG
microdata.55 Inpatient episode costs were the sum of hospita-
lization and follow-up costs occurring after hospital discharge.
Table 3. Demographic and epidemiological parameters.
Portugal population, by age and risk groupa
Age group Population Low risk Moderate risk High risk
18–49 4,080,167 88.9% 8.6% 2.4%
50–64 1,987,704 72.4% 21.6% 6.0%
65–74 1,017,870 62.1% 30.6% 7.3%
75–84 734,643 57.3% 33.2% 9.5%
> 84 246,150 62.2% 28.3% 9.5%
Total 8,066,534 63.6% 14.2% 3.5%
Annual incidence of invasive pneumococcal diseases and all-cause pneumonia per 100,000 persons assuming no vaccinationb
Age group Bacteremia and sepsis Meningitis Pneumonia inpatient Pneumonia outpatient
18–49 3.49 1.02 53.87 315.76
50–64 8.51 2.92 199.68 754.21
65–74 11.07 3.47 548.20 1,325.38
75–84 21.32 5.04 1,780.73 2,449.95
> 84 54.47 5.28 5,243.96 3,349.64
Total 8.86 2.29 467.84 838.16
Mortality rates for the general population and fatality rates of IPD and pneumoniac
Age group General population adjusted mortality Bacteremia and sepsis Meninigits Pneumonia (inpatient)
18–49 0.08% 4.26% 6.0% 5.37%
50–64 0.37% 3.80% 6.0% 11.04%
65–74 1.12% 2.79% 6.0% 16.81%
75–84 3.48% 7.65% 6.0% 22.44%
> 84 15.19% 7.40% 6.0% 30.82%
Total 1.05% 4.37% 6.0% 10.54%
Health-state utility and yearly disutilitiesd
Age group General population Bacteriemia and sepsis Meningitis Pneumonia inpatient Pneumonia outpatient
18–49 0.90 0.0079 0.0232 0.0060 0.0040
50–64 0.80 0.0079 0.0232 0.0060 0.0040
65–74 0.74 0.0079 0.0232 0.0060 0.0040
75–84 0.66 0.0079 0.0232 0.0060 0.0040
>84 0.53 0.0079 0.0232 0.0060 0.0040
aINE 2014,50 NHS 2005/200651 and INSA 201352, INSA 201453 and authors’ estimations. bDRG 201355 and Prof. Dr. Melo Cristino, 2013. cINE 2013,57 INE 2014,58 DRG 201355
and authors’ estimations. dSisk et al. 2003,59 and Melegaro and Edmunds 2004.60
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Portuguese NHS tariffs, in particular Order no. 20/2014, were
used as the source of unitary costs. Due to the small number
of meningitis episodes registered in the database, an average
cost was used for all age groups.
Follow-up costs after hospitalization were estimated accord-
ing to the opinion of a nationally representative panel of experts
and by applying Order no. 20/2014 tariffs for unitary costs.
Meningitis, bacteremia and sepsis follow-up consumption
included two physician visits and two sets of blood tests,2 result-
ing in a cost estimate of €90.54 per episode. For pneumonia,
experts considered that follow-up included one set of blood tests,
with 20% of the patients having two physician visits, 30% of the
patients measuring oximetry and all receiving a chest X-ray.
Pneumonia follow-up costs were estimated at €98.2 per episode.
Pneumonia costs per outpatient episode were estimated at
€137, including two physician visits and chest X-rays for all
patients, emergency department admission for 70% of the
patients and a set of blood tests for 10% of the patients.
Prescription drugs were also included in the cost estimates.
Vaccine acquisition costs were taken from INFOMED
(INFARMED drug database).72 Value-added tax was excluded
and an administration cost of €3.70 was considered.3 The
overall cost per vaccine administration resulted in €15.59
and €59.46 for PPSV23 and PCV13, respectively. In the base-
case scenario, vaccination was assumed to occur in the con-
text of regular contacts with the health system that would
have occurred anyway. Therefore, additional travel costs
were not included in the base-case scenario.
The study adopted a societal perspective as recommended
by INFARMED guidelines for economic evaluation.48 The
cost related to employees’ lost productivity was the only
indirect cost included. The work cost per day was computed
using the average wage in official labor market statistics73 and
adjusted for the employment rate as reported in the employ-
ment survey of the 4th quarter of 2014.74 Disease-attributable
work-loss days were approximated as two times the average
length of stay observed in the DRG database for inpatient
episodes. For outpatient pneumonia episodes, 7 work-loss
days were assumed. The overall direct and indirect costs per
episode are presented by age and PD group (Table 4).
Sensitivity analysis
In order to assess the robustness of these results in relation to
the assumptions made in the base-case scenario, both uni-
variate analyses and PSAs were performed. In univariate ana-
lyses, the parameters more uncertain were varied, in
particular, the herd effect size resulting from childhood vac-
cination, the incidence rate of pneumonia in inpatient and
outpatient care, the effectiveness values of PCV13, the rate of
adults’ immunization, and alternative discount rates. We
further included a scenario where travel costs were considered
for 50% of the vaccinated population (Table 2).
In the PSA, 5,000 simulations were run simultaneously
varying several model parameters. Beta distributions were
assumed for incidence rates, effectiveness rates and case-
fatality rates. Lognormal distributions were used for costs,
while utilities were considered uniformly distributed.
Conclusions
This study shows that adult vaccination (aged 18 years and
older) in Portugal with PCV13 is cost-effective, producing
health gains at costs below the usual acceptable willingness
to pay threshold. The results are robust in all sensitivity
analyses, with the exception of the scenario where effective-
ness of PCV13 is very low. The PCV13 vaccination strategy is
associated with a reduction of the pneumococcal disease bur-
den, avoiding up to 5,712 deaths (compared with no vaccina-
tion) over the modelling horizon. These results strongly
suggest that PCV13 should be added to the national thera-
peutic arsenal for preventing pneumococcal disease in adults.
Notes
1. When estimating mortality rates, all bacteremia cases were con-
sidered due to the limited number of observations identified as
pneumococcal bacteremia.
2. Complete blood count, blood glucose test, urea, creatinine, iono-
gram, serum AST and PCR.
3. Unit cost based on Order no. 20/2014.
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Table 4. Direct and indirect costs per episode by age and disease (including










18–49 11,268.24 € 7,880.74 € 4,053.24€ 136.92 €
50–64 5,532.87 € 7,880.74 € 3,959.52€ 136.92 €
65–74 6,669.53 € 7,880.74 € 2,991.39€ 136.92 €
75–84 5,221.06 € 7,880.74 € 2,882.72 € 136.92 €
> 84 4,808.52 € 7,880.74 € 2,515.02 € 136.92 €
Indirect costs
18–49 1,288.78 € 795.64 € 674.96 € 244.55 €
50–64 1,260.45 € 938.72 € 731.96 € 239.47 €
65–74 138.62 € 163.87 € 137.24 € 41.80 €
75–84 0.00 € 0.00 € 0.00 € 0.00 €
> 84 0.00 € 0.00 € 0.00 € 0.00 €
Source: Experts’ opinion, DRG 201355 and order no. 20/2014.
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